Cooley advised Vir Biotechnology on its acquisition of Humabs BioMed and on entering into strategic agreements with Alnylam Pharmaceuticals, Visterra and four leading academic research institutions….
Vir Biotechnology’s acquisition of Humabs BioMed
Cooley advised Vir Biotechnology on its acquisition of Humabs BioMed and on entering into strategic agreements with Alnylam Pharmaceuticals, Visterra and four leading academic research institutions….